•  
  •  
  •  
  •  

2026-05-22 14:02:26

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Suzlon 3 MW platform sales reach nearly 9 GW with a new 195 MW order from Sunsure Energy
  • Manali Petrochemicals Q4 consolidated PAT jumps 169 pc to Rs 29 crore
  • Dow Scales New Heights Amid Crude Swings
  • Hindustan Foods delivers strong FY26 performance across all business verticals
  • Vintage Coffee and Beverages Ltd announces robust Q4FY26 results

Keywords Selected:  Release

Stock Report

  • TCS and Australian Securities Exchange go-live with CHESS Release 1 for cash clearing & settlement
  • Lupin Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
  • Lupin announces approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
  • Aurobindo Pharma receives USFDA Approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended-Release Tablets USP, 12.5 mg
  • Ola Electric Mobility Ltd sells stake to release pledged shares
  • Pritish Nandy Communications' Four More Shots Please! Season 4 Trailer Released on Prime Video
  • Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg
  • Biocon Pharma Ltd receives approval from USFDA for its ANDA
  • Zydus receives final approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval Dexlansoprazole Delayed Release Capsules, 30 mg and 60 mg
  • Zydus receives approval from China's NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg
  • Zydus receives tentative approval from USFDA for Budesonide delayedrelease capsules, 4 mg
  • Nisus Finance's Promoter Announces Release of Pledged Shares & Company pairing down its Loan Obligation
  • Zinema Media and Entertainment Ltd updates on release of Blackmail
  • Vrusshabha roars into Cinemas on November 6, 2025
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended Release Tablets USP, 25 mg and 37.5 mg.
  • Zinema Media and Entertainment Ltd to release tamil film BLACKMAIL
  • Lupin receives U.S. FDA approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Carbamazepine Extended-Release Tablets USP, 100 mg, 200 mg, and 400 mg
  • Gas Release Incident at ONGC Rudrasagar Field: Situation Under Control
  • Vrusshabha Releasing in Cinemas on October 16, 2025
  • Zydus receives final approval from USFDA for Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg
  • Pritish Nandy Communications and Netflix announce the release of The Royals, on May 9

Latest Post

  • Suzlon 3 MW platform sales reach nearly 9 GW with a new 195 MW order from Sunsure Energy
  • Manali Petrochemicals Q4 consolidated PAT jumps 169 pc to Rs 29 crore
  • Dow Scales New Heights Amid Crude Swings
  • Hindustan Foods delivers strong FY26 performance across all business verticals
  • Vintage Coffee and Beverages Ltd announces robust Q4FY26 results


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025